Biomarkers Go Beyond "All or None" Equation

Maurie Markman, MD
Published: Wednesday, Jan 31, 2018
Maurie Markman, MD
Maurie Markman, MD
The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature: What is the significance of a biomarker when a drug benefits not only patients with that characteristic but also those without it?
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x